Bisphosphonates and Tumor Burden
- 1 August 2002
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (15), 3191-3192
- https://doi.org/10.1200/jco.2002.20.15.3191
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast CancerJournal of Clinical Oncology, 2002
- Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled TrialJournal of Clinical Oncology, 2001
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate TreatmentNew England Journal of Medicine, 1998
- Oral Clodronate and Reduction in Loss of Bone Mineral Density in Women With Operable Primary Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Overview of bisphosphonatesCancer, 1997
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996